Sichuan Kelun-Biotech Biopharmaceutical Co Ltd, a holding subsidiary of Kelun Pharmaceutical (SZ:002422), announced on Monday that the new drug application (NDA) for its small molecule rearranged during transfection (RET) kinase inhibitor A400 (EP0031) has been accepted for review by the Center for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA).
The product is intended for the treatment of adult patients with RET-fusion positive locally advanced, or metastatic non-small cell lung cancer (NSCLC).
This acceptance for review is based on positive results from the two pivotal Phase 2 cohorts of the KL400-I/II-01 study for both 1L and 2L+ advanced RET-fusion positive NSCLC.
Genetic Analysis AS launches new microbiome diagnostic tool for the global research market
BioArctic secures Australian approval for Alzheimer's drug Leqembi
Sanofi's SAR446268 receives FDA fast track designation for myotonic dystrophy type 1
New Study Shows Poor Inventory Practices Are Restricting Growth for HME|DME Providers
MavriX Bio receives Fast Track designation from FDA for MVX-220
GC Biopharma submits IND application in South Korea for Phase 1 trial of COVID-19 vaccine candidate
Sichuan Kelun-Biotech Biopharmaceutical NDA for A400 accepted for review in China
Akeso showcasing late-breaking abstract from ivonescimab study at ESMO
Neurocrine Biosciences reports positive phase 2 results for osavampator in major depressive disorder
Tempus secures FDA clearance for RNA-based xR IVD diagnostic device
Thermo Fisher unveils Hypulse System for advanced surface analysis
Regenerative Agriculture Pioneer Bob Jones to Deliver Keynote at Metabolic Health Day Conference
N4 Pharma advances RNA delivery breakthrough with SRI collaboration
Genentech reports positive Phase III results for giredestrant in ER-positive advanced breast cancer